# Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S.

- **DOI:** [10.1016/j.jacig.2026.100750](https://doi.org/10.1016/j.jacig.2026.100750)
- **Rating:** Limited (2.5 out of 5)
- **Verdict:** A larger descriptive dataset documents sebetralstat use during long-term prophylaxis, but uncontrolled treatment selection prevents its broad effectiveness conclusions.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-02
- **Evaluation page:** https://www.nabu.science/paper/10.1016%2Fj.jacig.2026.100750

## Key claims

1. In conclusion, results of this interim analysis of the KONFIDENT-S study demonstrate that sebetralstat is a safe, well-tolerated, and effective on-demand treatment for breakthrough attacks in patients receiving LTP, regardless of the LTP mechanism of action.
   - Support: Tentative
   - Type: Primary finding
   - Basis: uncontrolled, self-selected treatment episodes cannot establish causal effectiveness or effectiveness across prophylaxis mechanisms
   - Location: Discussion, final paragraph
2. No serious or severe treatment-related treatment-emergent adverse events were reported.
   - Support: Supported
   - Type: Secondary
   - Basis: participant-level reporting supports the observed absence, but 35 participants and incompletely described ascertainment limit safety inference
   - Location: Abstract, Results
3. Effectiveness was similar for participants receiving berotralstat, lanadelumab, or C1 inhibitor.
   - Support: Tentative
   - Type: Secondary
   - Basis: unpowered prophylaxis groups, including six C1INH participants, cannot establish comparative similarity
   - Location: Abstract, Results

## Strengths

- **Larger dataset addresses a documented clinical gap** The analysis reports 382 sebetralstat-treated breakthrough attacks in 35 participants receiving prophylaxis, extending the parent trial's 58 attacks in 24 such participants. This adds descriptive evidence in a concomitant-treatment setting identified as underreported.
  - Dimension: contribution
  - Location: Introduction, final three paragraphs; Results, Attack Frequency and Treatment Patterns
- **Safety outcomes retain clear participant denominators** Table III separates serious, severe, treatment-related, and discontinuation events by prophylaxis group. The accompanying text explains both discontinuations and reports no serious or severe sebetralstat-related events.
  - Dimension: methodological rigour
  - Location: Table III; Results, Safety
- **Treatment choices and rescue use remain visible** The results distinguish sebetralstat-first, conventional-treatment-first, and untreated attacks, alongside second dosing and rescue treatment. Reporting the greater proportion of laryngeal attacks treated conventionally helps readers assess treatment selection.
  - Dimension: reporting
  - Location: Results, Attack Frequency and Treatment Patterns, Treated Attack Characteristics, and Effectiveness

## Limitations

- **Uncontrolled attack selection prevents causal effectiveness inference** Participants chose which attacks received sebetralstat first, and effectiveness outcomes were not collected for conventional-treatment-first attacks. Without a concurrent comparator, observed symptom trajectories cannot establish the treatment's causal benefit.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Participants and Primary and Secondary Objectives
- **Primary safety reporting lacks ascertainment and exposure** The paper reports event counts, grading, and relatedness but does not describe how adverse events were elicited or provide subgroup exposure duration. These omissions limit interpretation of its primary safety objective.
  - Dimension: methodological rigour
  - Location: Methods, Primary and Secondary Objectives; Table III; Results, Safety
- **Mechanism-wide conclusions contradict acknowledged limits on comparisons** The limitations state that LTP-agent comparisons were unpowered and that the six-participant C1INH group may not be representative. The abstract nevertheless reports similar effectiveness across agents, and the conclusion asserts effectiveness regardless of mechanism.
  - Dimension: positioning
  - Location: Abstract, Results and Conclusion; Discussion, Limitations and final paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. 2 reported values do not reconcile, but the key claims do not rest on them.
  - Treatment of breakthrough attacks with sebetralstat resulted in rapid symptom relief: "Of the 382 attacks, 264 (69.1%) obtained beginning of symptom relief within 12 hours." (Results, Effectiveness) vs "Median (IQR) time to beginning of symptom relief was 1.3 (0.8-3.8) hours for participants receiving any LTP" (Results, Effectiveness). Under an uncensored empirical-distribution approximation, 69.1% reaching relief by 12 hours would place the upper quartile beyond 12 hours, but censoring may explain the reported 3.8-hour quartile. → Effect on result unclear
  - Minor reporting notes (1):
    - Descriptive: "Overall, 29.6% of breakthrough attacks were mild at the time of treatment." (Results, Treated Attack Characteristics) vs "Mild112 (29.3)58 (32.6)24 (30.0)30 (24.2)" (Table II). 112/382 = 29.3%, not 29.6%, and the table footnote accounts for the additional attack rated none. → Conclusion holds
- **Reporting and transparency:** Noted. Ethics approval, consent, trial registrations, funding, and conflicts are declared. The reported 6-minute treatment interval is inconsistently labeled as beginning at attack recognition or attack onset.
  - Conflict of interest: declared · Ethics approval: declared · Preregistration: declared
- **Reference integrity:** Clean
  - 46 references in manuscript
  - 26 of 26 checkable references found in an index
  - 20 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-02
